Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Burning Rock Biotech (BNR) Operating Expenses: 2019-2025

Historic Operating Expenses for Burning Rock Biotech (BNR) over the last 6 years, with Sep 2025 value amounting to $183.4 million.

  • Burning Rock Biotech's Operating Expenses fell 46.05% to $183.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$166.3 million, marking a year-over-year decrease of 129.46%. This contributed to the annual value of -$98.6 million for FY2024, which is 32.18% up from last year.
  • Latest data reveals that Burning Rock Biotech reported Operating Expenses of $183.4 million as of Q3 2025, which was up 184.65% from -$216.7 million recorded in Q2 2025.
  • In the past 5 years, Burning Rock Biotech's Operating Expenses ranged from a high of $844.5 million in Q4 2022 and a low of -$343.2 million during Q3 2022.
  • Its 3-year average for Operating Expenses is -$13.1 million, with a median of -$112.6 million in 2025.
  • The largest annual percentage gain for Burning Rock Biotech's Operating Expenses in the last 5 years was 1,569.02% (2022), contrasted with its biggest fall of 738.54% (2022).
  • Burning Rock Biotech's Operating Expenses (Quarterly) stood at -$57.5 million in 2021, then skyrocketed by 1,569.02% to $844.5 million in 2022, then dropped by 23.90% to $642.7 million in 2023, then plummeted by 103.18% to -$20.5 million in 2024, then tumbled by 46.05% to $183.4 million in 2025.
  • Its Operating Expenses was $183.4 million in Q3 2025, compared to -$216.7 million in Q2 2025 and -$112.6 million in Q1 2025.